Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2014年 / 12卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：10 / 11
页数：2
相关论文
共 50 条
  • [1] Phase II Trial Of Brentuximab Vedotin For CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2013, 122 (21)
  • [2] Phase II trial of Brentuximab vedotin (SGN-35) for CD30+cutaneous T-cell lymphomas and lymphoproliferative disorders
    Duvic, M.
    Tetzlaff, H.
    Gangar, P.
    Clos, A. L.
    Talpur, R.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S180 - S180
  • [3] Results of a Phase II Trial of Brentuximab Vedotin (SGN-35) for CD30+Cutaneous T-Cell Lymphomas and Lymphoproliferative Disorders
    Duvic, Madeleine
    Tetzlaff, Michael
    Clos, Audra L.
    Gangar, Pamela
    Talpur, Rakhshandra
    BLOOD, 2012, 120 (21)
  • [4] Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis
    Duvic, Madeleine
    Tetzlaff, Michael T.
    Gangar, Pamela
    Clos, Audra L.
    Sui, Dawen
    Talpur, Rakhshandra
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) : 3759 - +
  • [5] Brentuximab vedotin in CD30+ primary cutaneous T-cell lymphomas: a review and analysis of existing data
    Enos, Tyler H.
    Feigenbaum, Lawrence S.
    Wickless, Heather W.
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2017, 56 (12) : 1400 - 1405
  • [6] Brentuximab vedotin for the treatment of CD30+ lymphomas
    Foyil, Kelley V.
    Bartlett, Nancy L.
    IMMUNOTHERAPY, 2011, 3 (04) : 475 - 485
  • [7] CD30+ T-cell lymphoproliferative disorders
    Martin, James M.
    Wu, Hong
    Barta, Stefan K.
    CHINESE CLINICAL ONCOLOGY, 2019, 8 (01)
  • [8] Pathobiology of CD30+ cutaneous T-cell lymphomas
    Kadin, ME
    JOURNAL OF CUTANEOUS PATHOLOGY, 2006, 33 : 10 - 17
  • [9] Brentuximab Vedotin in the Front-Line Treatment of Patients With CD30+ Peripheral T-Cell Lymphomas: Results of a Phase I Study
    Fanale, Michelle A.
    Horwitz, Steven M.
    Forero-Torres, Andres
    Bartlett, Nancy L.
    Advani, Ranjana H.
    Pro, Barbara
    Chen, Robert W.
    Davies, Andrew
    Illidge, Tim
    Huebner, Dirk
    Kennedy, Dana A.
    Shustov, Andrei R.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (28) : 3137 - +
  • [10] Intralesional brentuximab vedotin: our experience in the treatment of CD30+primary cutaneous T-cell lymphomas
    Arroyo Andres, J. A.
    Rubio Muniz, C. A.
    Agud De Dios, M. A.
    Falkenhain Lopez, D.
    Mitsunaga, K.
    Sanchez Velazquez, A.
    Postigo Llorente, C.
    Ortiz-Romero, P. L.
    EUROPEAN JOURNAL OF CANCER, 2022, 173 : S50 - S51
12345